Hyrnuo (Sevabertinib)

Description

Hyrnuo is indicated for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring activating HER2 (ERBB2) mutations, who have received at least one prior systemic therapy.

What Hyrnuo is Used For

Hyrnuo is used in adults with:

• Locally advanced or metastatic non-squamous NSCLC
• Tumors that have HER2 (ERBB2) tyrosine kinase mutations
• Patients who have already received prior systemic cancer treatment

This makes it a targeted therapy, meaning it is designed to act on specific genetic changes in cancer cells.

---

How Hyrnuo Works

Hyrnuo works by inhibiting HER2-related signaling pathways inside cancer cells.
By blocking these signals, it helps:

• Slow down cancer cell growth
• Reduce tumor progression
• Potentially improve treatment response in eligible patients

---

Dosage and Administration

• Taken orally (by mouth)
• Usually taken at the same time every day
• Should be swallowed whole with water
• Taken with food (as directed by a doctor)
• Dose adjustments may be required based on side effects or response

---

Important Safety Information

Hyrnuo may cause side effects such as:

• Diarrhea (can be severe)
• Liver enzyme changes
• Eye problems (ocular toxicity)
• Lung inflammation (rare but serious)
• Pancreatic enzyme increases

Patients are usually monitored regularly during treatment to manage these risks.

---

Storage Information

• Store at room temperature (20–25°C)
• Keep in a dry place away from moisture and heat
• Keep out of reach of children and pets

---

Summary

Hyrnuo is a modern targeted cancer therapy designed for patients with HER2-mutated lung cancer. It is part of a growing group of precision medicines that focus on genetic markers rather than general chemotherapy approaches.

---